Saturday, May 26, 2018
 
 
Company News: Page (1) of 1 - 12/07/17 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Resverlogix Repays $68.8 Million Loan

(December 07, 2017)

CALGARY, Alberta, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has repaid, in full, its CAD$68.8 million Loan (the “Loan”). Upon repayment of the Loan, the Company has no outstanding long-term debt.

Mr. Donald McCaffrey, President and CEO commented, "Retiring the Loan in its entirety significantly strengthens Resverlogix’s financial position and increases our degrees of freedom as we move forward. We would like to thank Eastern Capital for its support in providing the letter of credit, which secured the Loan at a very favourable rate. This attractive financing permitted us to significantly advance the development of apabetalone (RVX-208), including the launch of the Phase 3 trial BETonMACE."

About Resverlogix

Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile. Apabetalone is the only selective BET bromodomain inhibitor in human clinical trials. Apabetalone is currently being studied in a Phase 3 trial, BETonMACE, in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL), and is expected to be initiated in a Phase 2a kidney dialysis trial designed to evaluate biomarker changes and safety parameters in up to 30 patients with end-stage renal disease treated with hemodialysis.

Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).

Follow us on Twitter: @Resverlogix_RVX (https://twitter.com/resverlogix_rvx)

For further information please contact:

Investor Relations

Email: [email protected] Phone: 403-254-9252


Or visit our website: www.resverlogix.com


Page: 1


Related Keywords:
Related Sites: DMN Newswire ,   USDailyNews ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • Bellevue Asset Management AG: Bellevue launches dedicated digital health fund
  • Global Chromatography Reagents Market Analysis, Growth, Trends & Forecast 2018-2023, With The Market Forecasted to Register a CAGR of More Than 7% - ResearchAndMarkets.com
  • Life Science Reagents Market to exceed US$ 67.0 Bn by 2026, Says TMR
  • Study on Poor Oral Hygiene Habits of Aging Population Underlines the Importance of Outstanding Dental Care, says Premier Care Dental Group
  • Blood Gas and Electrolyte Analyzer Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2023

    Cancer
  • Bavarian Nordic Announces Interim Results for the First Three Months of 2018
  • NASP Applauds Bipartisan Legislation Introduced to Reduce Drug Costs and Support Access for Seniors with Life-Threatening Specialized Conditions
  • Celgene Corporation Announces Additional $3 Billion Share Repurchase Authorization and Plans to Execute a $2 Billion Accelerated Share Repurchase Program
  • Moorestown Visiting Nurse Association joins the growing enTouch network in New Jersey
  • Achieve Life Sciences, Inc. Announces Reverse Stock Split
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines